Publication | Closed Access

Antitumor agents XLII: Comparison of Antileukemic Activity of Helenalin, Brusatol, and Bruceantin and their Esters on Different Strains of p-388 Lymphocytic Leukemic Cells

Hematological MalignancyLymphoid NeoplasiaAntitumor AgentsDifferent StrainsAntileukemic ActivityImmunologyMedicineAnti-cancer AgentImmunotherapyPharmacologyDrug Discovery